Solventum Co. (NYSE:SOLV) Shares Sold by Aspiriant LLC

Aspiriant LLC lessened its position in shares of Solventum Co. (NYSE:SOLV) by 4.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,554 shares of the company’s stock after selling 151 shares during the period. Aspiriant LLC’s holdings in Solventum were worth $235,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Copeland Capital Management LLC acquired a new position in Solventum in the third quarter valued at approximately $26,000. Modus Advisors LLC bought a new stake in shares of Solventum in the 4th quarter worth approximately $25,000. Mather Group LLC. acquired a new position in Solventum during the 3rd quarter valued at approximately $27,000. True Wealth Design LLC grew its stake in Solventum by 23,550.0% during the 3rd quarter. True Wealth Design LLC now owns 473 shares of the company’s stock worth $33,000 after buying an additional 471 shares during the last quarter. Finally, Prospera Private Wealth LLC acquired a new stake in Solventum in the third quarter worth $35,000.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Wolfe Research started coverage on shares of Solventum in a research report on Thursday, September 26th. They set a “peer perform” rating for the company. Mizuho initiated coverage on shares of Solventum in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price target on the stock. Piper Sandler boosted their price objective on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. Stifel Nicolaus initiated coverage on Solventum in a research report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 target price on the stock. Finally, Morgan Stanley boosted their price target on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, Solventum has a consensus rating of “Hold” and an average target price of $68.29.

Solventum Stock Up 0.6 %

Shares of SOLV stock opened at $73.94 on Wednesday. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. The business’s fifty day moving average is $69.16 and its 200-day moving average is $65.85. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $96.05.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Thursday, November 7th. The company reported $1.15 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.23). The business had revenue of $2.08 billion for the quarter, compared to analysts’ expectations of $2.05 billion. Analysts forecast that Solventum Co. will post 6.58 EPS for the current fiscal year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.